Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DC-based neoantigen vaccine
- Development stage
- Unknown
- Lead developer
- YUCEBIO
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
A personalized cancer immunotherapy that utilizes autologous dendritic cells (DCs) loaded with patient-specific neoantigens. Neoantigens are unique proteins derived from somatic mutations within a patient's tumor, identified through whole-exome sequencing (WES) and RNA sequencing. By presenting these neoepitopes to the immune system, the vaccine aims to elicit a potent and specific T-cell response (both CD4+ and CD8+) against tumor cells while avoiding central tolerance. This approach is being investigated for various advanced malignancies, including small cell lung carcinoma (SCLC) with brain metastasis, to overcome resistance to standard therapies like chemotherapy and PD-1 inhibitors.
- Other names
- personalized neoantigen-based cancer vaccineautologous DC-based neoantigen vaccinedendritic cell-based neoantigen vaccine
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on DC-based neoantigen vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DC-based neoantigen vaccine.